Navigation Links
Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data
Date:4/17/2008

ctive in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO,

Tel: +41-61-417-96-60;

Harry Welten, MBA, CFO and Senior Vice President,

Tel: +41-61-417-96-65;

Paul Verbraeken, Head of Corporate Communications,

Tel: +41-61-417-96-83.


'/>"/>
SOURCE Arpida
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
5. New knock-out gene model provides molecular clues to breast cancer
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. SIV infection of natural hosts provides new insights into HIV disease complexity
8. Microarray provides 3 genomic guides to breast cancer treatment decisions
9. Access Innovations Provides Support Services for Agis Network
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Physical Therapist Provides Injury Analysis for Fantasy Football
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Jvion, the Atlanta-based leader in ... Clostridium Difficile (C Diff) predictive use case for ... case is the latest in a broad compliment ... chronic conditions, and individual illnesses. Using the firm’s ... flags at risk individuals to help support clinician ...
(Date:3/6/2015)... TX (PRWEB) March 06, 2015 Yisrayl ... in Abilene, Texas, has released a new publication explaining ... working. , The article titled “Microorganisms Do ... document explaining how tiny microorganisms were created and designed ... is aware of some of the functions of these ...
(Date:3/6/2015)... Springs, FL (PRWEB) March 06, 2015 The ... present March 2015 air dates for Spokane, Washington and vicinity. ... colorful places to shop and dine, and many outdoor activities. ... industry supporting the local economy. Six major hospitals call the ... to the Canadian border. The medically-focused cable TV program will ...
(Date:3/6/2015)... March 06, 2015 The Public ... awarded five-year accreditation status to seven more health departments. ... another 1.3 million people can now be assured that ... promote the health of their communities. , Public health ... the health of people and communities. Across the nation, ...
(Date:3/5/2015)... 2015 This week, 60 ... low-cost laminate flooring products, initiating widespread concern from ... building materials made primarily from bamboo, stands behind ... their flooring products for volatile organic compounds (VOCs) ... International (BMH). Results from formaldehyde emissions testing ...
Breaking Medicine News(10 mins):Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:Yisrayl Hawkins Tells Scientists Exactly What Makes Life Function Properly in New Publication 2Health News:The Health Briefs TV Show to Air in Spokane, Washington 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2
... -- The role that air pollution plays in heart ... be underestimated, according to researchers. A small study ... changes in the heart,s electrical system when the participants ... that air pollution may interfere with the heart,s ability ...
... By Randy Dotinga HealthDay Reporter , TUESDAY, ... people walk may provide a glimpse into how many years ... that a formula that includes gait predicted older people,s future ... health conditions as blood pressure and heart disease. Walking ...
... for the 2013 America,s Cup has been announced, a study ... smooth sailing. The study was published recently in the journal ... survey completed by sailors, researchers at Rhode Island Hospital have ... two types of boats -- dinghies (small boats with crews ...
... TUESDAY, Jan. 4 (HealthDay News) -- Rates of head and ... young women without any known risk factors. Now, a study ... the movement of precancerous cells in the mouth. ... estrogen after the lungs are exposed to smoke. This may ...
... 2011 - Normally, cortical nerve cells or neurons reside in ... in the white matter, but some people with schizophrenia have ... migration errors may arise in schizophrenia as a consequence of ... aberrant cellular localization has now been studied in detail in ...
... the leading cause of death in the developed world. ... have been defined, scientists continue to study other possible ... studies link infectious agents with the development of inflammatory ... pathogen Porphyromonas gingivalis is the induction of ...
Cached Medicine News:Health News:Fast Walkers May Have More Years Ahead of Them 2Health News:Fast Walkers May Have More Years Ahead of Them 3Health News:Watch out for that boom 2Health News:Watch out for that boom 3Health News:Estrogen May Play Role in Rising Rates of Head, Neck Cancer 2Health News:Neuronal migration errors: Right cells, wrong place 2Health News:Porphyromonas gingivalis accelerates inflammatory atherosclerosis in a mouse model 2
(Date:3/5/2015)... 5, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... and technology platform company serving the pharmaceutical, biotechnology, and ... United States, today announced its financial results for the ... Fourth-Quarter 2014 Highlights , Net Revenues Increased 21.3% ... Services Net Revenues Grew 17.7% Year Over Year to ...
(Date:3/5/2015)... and TÜBINGEN, Germany , ... Melinda Gates Foundation and CureVac today announced that ... $52 million (€46 million) in CureVac, a leading ... As part of the agreement, the foundation will ... develop prophylactic vaccines based on CureVac,s proprietary messenger ...
(Date:3/5/2015)... 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... ended January 31, 2015 on Thursday, March 12 before the ... results at 11:00 AM ET. To participate ... 10 minutes before the beginning of the call. If you ... will be available from Thursday, March 12, 2015 through midnight ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... ... Salt Lake City based software company, announces the launch of a new ... in conjunction with existing in-office therapy methods. , eyeQ was ... elect, Dr. Brad Habermehl believes the eyeQ program adds significant ...
... , FRANKLIN, Mass., Nov. 24 ... company developing its needle-free Symphony(TM) tCGM System as a ... its Prelude(TM) SkinPrep System for transdermal drug delivery, announced ... Executive Officer, will present at the 13th Annual Biotech ...
Cached Medicine Technology:Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
ROB-NEL Catheters (100% Latex-Free)...
Red Rubber Robinson Catheters (Latex)...
Urethral Red Rubber Catheters (Latex)...
Medicine Products: